Health Economics›Gallbladder cancer›Adjuvant therapy

Adjuvant therapy

Gallbladder cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine and Gemcitabine Variant #06	—	R 17 897	56d	—	~7.9 mo	—	—	6
Capecitabine and RT Variant #07	—	R 4 675	38d	—	—	—	—	2
GemOx Variant #01	—	R 2 335	14d	—	~9.3 mo	—	—	2
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~5.7 mo	~7.5 mo	~9	~R 19 974 PFS proxy · indirect	11
Observation Partial	—	—	—	~3.4 mo	~36.1 mo	—	—	18
S-1 monotherapy Variant #01 Partial	—	—	21d	~1.7 mo	~10.5 mo	~3	—	13

6 of 6 regimens shown